DOCSLIB.ORG

Nevada Medicaid Formulary

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Nevada Medicaid Formulary Nevada Medicaid-Approved Preferred Drug List Effective August 15, 2021 Legend In each class, drugs are listed alphabetically by either brand name or generic name. Brand name drug: Uppercase in bold type Generic drug: Lowercase in plain type AL: Age Limit Restrictions DO: Dose Optimization Program GR: Gender Restriction OTC: Over the counter medication available with a prescription. (Prescribers please indicate OTC on the prescription) PA: Prior authorization is required. Prior authorization is the process of obtaining approval of benefits before certain prescriptions are filled. QL: Quantity limits; certain prescription medications have specific quantity limits per prescription or per month. SP: Specialty Pharmacy ST: Step therapy is required. You may need to use one medication before benefits for the use of another medication can be authorized. Drug Name Reference Notes *ADHD/ANTI-NARCOLEPSY/ANTI- OBESITY/ANOREXIANTS* *ADHD AGENT - SELECTIVE ALPHA ADRENERGIC AGONISTS*** clonidine hcl er oral tablet extended release Kapvay AL; QL 12 hour *ADHD AGENT - SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR*** atomoxetine hcl oral capsule Strattera DO; AL; QL *AMPHETAMINE MIXTURES*** amphetamine-dextroamphet er oral capsule extended release 24 hour 10 mg, 15 mg, 5 Adderall XR DO; AL; QL mg amphetamine-dextroamphet er oral capsule extended release 24 hour 20 mg, 25 mg, 30 Adderall XR AL; QL mg amphetamine-dextroamphetamine oral Adderall DO; AL; QL tablet 10 mg, 12.5 mg, 15 mg, 5 mg, 7.5 mg amphetamine-dextroamphetamine oral Adderall AL tablet 20 mg, 30 mg *AMPHETAMINES*** dextroamphetamine sulfate er oral capsule Dexedrine AL; QL extended release 24 hour dextroamphetamine sulfate oral tablet 10 mg Zenzedi PA; QL dextroamphetamine sulfate oral tablet 5 mg Zenzedi DO; AL; QL *ANALEPTICS*** caffeine citrate intravenous solution Cafcit caffeine citrate oral solution *LIPASE INHIBITORS*** ALLI ORAL CAPSULE PA; OTC; QL *STIMULANTS - MISC.*** dexmethylphenidate hcl er oral capsule extended release 24 hour 10 mg, 15 mg, 20 Focalin XR DO; AL; QL mg, 5 mg dexmethylphenidate hcl er oral capsule extended release 24 hour 25 mg, 30 mg, 35 Focalin XR AL; QL mg, 40 mg dexmethylphenidate hcl oral tablet 10 mg Focalin AL; QL dexmethylphenidate hcl oral tablet 2.5 mg Focalin DO; AL; QL 2 Drug Name Reference Notes dexmethylphenidate hcl oral tablet 5 mg Focalin PA; DO; QL methylphenidate hcl er (cd) oral capsule DO; AL; QL extended release 10 mg, 20 mg, 30 mg methylphenidate hcl er (cd) oral capsule AL; QL extended release 40 mg, 50 mg, 60 mg methylphenidate hcl er (la) oral capsule AL; QL extended release 24 hour methylphenidate hcl er oral tablet extended DO; AL; QL release 10 mg methylphenidate hcl er oral tablet extended Concerta DO; AL; QL release 18 mg, 27 mg methylphenidate hcl er oral tablet extended AL; QL release 20 mg methylphenidate hcl er oral tablet extended DO; AL; QL release 24 hour 18 mg, 27 mg methylphenidate hcl er oral tablet extended AL; QL release 24 hour 36 mg, 54 mg methylphenidate hcl er oral tablet extended Concerta AL; QL release 36 mg, 54 mg methylphenidate hcl oral solution Methylin AL methylphenidate hcl oral tablet 10 mg, 5 mg Ritalin DO; AL; QL methylphenidate hcl oral tablet 20 mg Ritalin AL *ALTERNATIVE MEDICINES* *ALTERNATIVE MEDICINE - ME'S*** cvs melatonin extra strength oral liquid OTC cvs melatonin gummies oral tablet chewable VitaJoy Gummies OTC cvs melatonin oral capsule OTC cvs melatonin oral liquid OTC cvs melatonin oral tablet 3 mg OTC cvs melatonin oral tablet 5 mg OTC; QL cvs melatonin oral tablet dispersible OTC cvs melatonin sublingual tablet sublingual OTC cvs quality sleep oral capsule OTC gnp melatonin maximum strength oral tablet OTC; QL gnp melatonin oral tablet OTC gnp melatonin oral tablet chewable VitaJoy Gummies OTC gnp melatonin sublingual tablet sublingual OTC hm melatonin quick dissolve oral tablet OTC dispersible 3 Drug Name Reference Notes hm melatonin sublingual tablet sublingual OTC kp melatonin oral tablet OTC max melatonin oral tablet dispersible OTC Zarbees Sleep melatonin childrens oral tablet chewable OTC Child/Melatonin melatonin er oral tablet extended release OTC melatonin extra strength oral liquid OTC melatonin gummies oral tablet chewable VitaJoy Gummies OTC melatonin maximum strength oral tablet 10 OTC mg melatonin maximum strength oral tablet 5 OTC; QL mg melatonin oral capsule OTC Zarbees Sleep melatonin oral liquid OTC Child/Melatonin melatonin oral tablet 1 mg, 10 mg, 3 mg, 300 OTC mcg melatonin oral tablet 5 mg OTC; QL melatonin oral tablet chewable VitaJoy Gummies OTC melatonin oral tablet dispersible OTC melatonin quick dissolve sublingual tablet OTC sublingual melatonin sublingual tablet sublingual OTC melatonin tr oral tablet extended release OTC mm melatonin oral tablet extended release OTC qc melatonin max st oral tablet OTC; QL ra melatonin oral tablet 10 mg, 3 mg OTC ra melatonin oral tablet 5 mg OTC; QL sm melatonin oral tablet OTC sm melatonin oral tablet dispersible OTC sv melatonin oral tablet OTC; QL sv melatonin oral tablet dispersible OTC VITAJOY GUMMIES ORAL TABLET OTC CHEWABLE ZARBEES SLEEP CHILD/MELATONIN OTC ORAL LIQUID *AMINOGLYCOSIDES* *AMINOGLYCOSIDES*** neomycin sulfate oral tablet 4 Drug Name Reference Notes paromomycin sulfate oral capsule Humatin tobramycin inhalation nebulization solution Kitabis Pak SP; QL *ANALGESICS - ANTI- INFLAMMATORY* *ANTI-TNF-ALPHA - MONOCLONAL ANTIBODIES*** HUMIRA PEDIATRIC CROHNS START SUBCUTANEOUS PREFILLED SYRINGE PA; SP; QL KIT HUMIRA PEN SUBCUTANEOUS PEN- PA; SP; QL INJECTOR KIT HUMIRA PEN-CD/UC/HS STARTER PA; SP; QL SUBCUTANEOUS PEN-INJECTOR KIT HUMIRA PEN-PEDIATRIC UC START PA; SP; QL SUBCUTANEOUS PEN-INJECTOR KIT HUMIRA PEN-PS/UV/ADOL HS START PA; SP; QL SUBCUTANEOUS PEN-INJECTOR KIT HUMIRA PEN-PSOR/UVEIT STARTER PA; SP; QL SUBCUTANEOUS PEN-INJECTOR KIT HUMIRA SUBCUTANEOUS PREFILLED PA; SP; QL SYRINGE KIT *GOLD COMPOUNDS*** RIDAURA ORAL CAPSULE *NONSTEROIDAL ANTI- INFLAMMATORY AGENTS (NSAIDS)*** ADDAPRIN ORAL TABLET PA; OTC; QL ADVIL JUNIOR STRENGTH ORAL OTC TABLET ADVIL JUNIOR STRENGTH ORAL OTC TABLET CHEWABLE ADVIL LIQUI-GELS MINIS ORAL OTC CAPSULE all day pain relief oral tablet Mediproxen OTC; QL all day relief oral tablet Mediproxen OTC; QL childrens ibuprofen 100 oral suspension Childrens Medi-Profen OTC; QL childrens ibuprofen oral suspension Childrens Medi-Profen OTC; QL CHILDRENS MEDI-PROFEN ORAL OTC; QL SUSPENSION cvs all day pain relief oral tablet Mediproxen OTC; QL 5 Drug Name Reference Notes cvs childrens ibuprofen oral suspension Childrens Medi-Profen OTC; QL cvs ibuprofen childrens oral suspension Childrens Medi-Profen OTC; QL cvs ibuprofen infants oral suspension Medi-Profen OTC; QL cvs ibuprofen junior strength oral tablet Advil Junior Strength OTC chewable cvs ibuprofen oral capsule Advil Liqui-Gels minis PA; OTC cvs ibuprofen oral tablet Addaprin OTC; QL cvs naproxen sodium oral capsule Aleve OTC cvs naproxen sodium oral tablet Mediproxen OTC; QL diclofenac potassium oral tablet Cataflam diclofenac sodium er oral tablet extended PA; QL release 24 hour diclofenac sodium oral tablet delayed QL release eq all day pain relief oral tablet Mediproxen OTC; QL eq ibuprofen childrens oral suspension Childrens Medi-Profen OTC; QL eq ibuprofen junior oral tablet chewable Advil Junior Strength OTC eq ibuprofen oral capsule Advil Liqui-Gels minis PA; OTC eq ibuprofen oral tablet Addaprin PA; OTC; QL eq naproxen sodium oral capsule Aleve OTC eq naproxen sodium oral tablet Mediproxen OTC; QL eql childrens ibuprofen oral suspension Childrens Medi-Profen OTC; QL eql ibuprofen infants oral suspension Medi-Profen OTC; QL eql ibuprofen junior strength oral tablet Advil Junior Strength OTC chewable eql ibuprofen oral capsule Advil Liqui-Gels minis PA; OTC eql ibuprofen oral tablet Addaprin OTC; QL eql naproxen sodium oral capsule Aleve OTC eql naproxen sodium oral tablet Mediproxen OTC; QL etodolac er oral tablet extended release 24 QL hour etodolac oral capsule QL etodolac oral tablet QL fenoprofen calcium oral capsule Nalfon PA fenoprofen calcium oral tablet Nalfon flurbiprofen oral tablet QL gnp childrens ibuprofen oral suspension Childrens Medi-Profen OTC; QL gnp ibuprofen childrens oral tablet chewable Advil Junior Strength OTC 6 Drug Name Reference Notes gnp ibuprofen infants oral suspension Medi-Profen OTC; QL gnp ibuprofen oral capsule Advil Liqui-Gels minis PA; OTC gnp ibuprofen oral tablet Addaprin OTC; QL gnp naproxen sodium oral capsule Aleve OTC gnp naproxen sodium oral tablet Mediproxen OTC; QL goodsense ibuprofen childrens oral Childrens Medi-Profen OTC; QL suspension goodsense ibuprofen infants oral suspension Medi-Profen OTC; QL goodsense ibuprofen oral capsule Advil Liqui-Gels minis PA; OTC goodsense ibuprofen oral tablet Addaprin OTC; QL goodsense naproxen sodium oral tablet Mediproxen OTC; QL hm ibuprofen childrens oral suspension Childrens Medi-Profen OTC; QL hm ibuprofen ib oral tablet Addaprin OTC; QL hm ibuprofen ib oral tablet chewable Advil Junior Strength OTC hm ibuprofen infants oral suspension Medi-Profen OTC; QL hm ibuprofen oral capsule Advil Liqui-Gels minis PA; OTC hm ibuprofen oral tablet Addaprin OTC; QL hm naproxen sodium oral capsule Aleve OTC hm naproxen sodium oral tablet Mediproxen OTC; QL hy-vee all day relief oral tablet Mediproxen OTC; QL HYVEE IBUPROFEN CHILDRENS ORAL OTC; QL SUSPENSION IBU ORAL TABLET QL ibu-200 oral tablet Addaprin OTC; QL ibuprofen 100 junior strength oral tablet Advil Junior Strength OTC chewable ibuprofen childrens oral suspension Childrens Medi-Profen
Load more

Recommended publications
  • Additions and Deletions to the Drug Product List
    Prescription and Over-the-Counter Drug Product List 40TH EDITION Cumulative Supplement Number 09 : September 2020 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACETAMINOPHEN; BUTALBITAL; CAFFEINE TABLET;ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE >A> AA STRIDES PHARMA 325MG;50MG;40MG A 203647 001 Sep 21, 2020 Sep NEWA ACETAMINOPHEN; CODEINE PHOSPHATE SOLUTION;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >D> AA WOCKHARDT BIO AG 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC >A> @ 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC TABLET;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >A> AA NOSTRUM LABS INC 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >A> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >A> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN >D> AA TEVA 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >D> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >D> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN ACETAMINOPHEN; HYDROCODONE BITARTRATE TABLET;ORAL HYDROCODONE BITARTRATE AND ACETAMINOPHEN >A> @ CEROVENE INC 325MG;5MG A 211690 001 Feb 07, 2020 Sep CAHN >A> @ 325MG;7.5MG A 211690 002 Feb 07, 2020 Sep CAHN >A> @ 325MG;10MG A 211690 003 Feb 07, 2020 Sep CAHN >D> AA VINTAGE PHARMS 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >A> @ 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >D> AA 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >A> @ 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >D> AA 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >A> @ 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >D> @ XIROMED 325MG;5MG A 211690
    [Show full text]
  • Stomachache Relief
    Stomachache Relief Abdominal pain has many causes. Only rarely is the cause serious. The general information section of Pediatric Planet has more information about when to be concerned. If your child’s physician has determined that there is not a serious cause of the abdominal pain there are a number of over-the-counter medications that may be helpful. The key to getting benefit is choosing the right medication for the job. Having some opinion from your child’s doctor regarding the probable cause of the discomfort is a good start. Constipation may cause abdominal pain when gas is trapped behind blockages of hard stool. In this case see the constipation relief section of the medicine cabinet for more information. Abdominal pain may also accompany lactose intolerance. If your child is lactose intolerant avoidance of milk products and use of supplemental lactase (Dairy-ease, Lactaid), when necessary, will be helpful. Active ingredients: Aluminum Hydroxide (solitary active ingredient in some Amphojel, one of several active ingredients in some Gaviscon, Maalox, and Mylanta products). Aluminum hydroxide is an effective neutralizer of stomach acid although it does not work as quickly as calcium carbonate. It has a more prolonged effect, however, and does not cause bloating. Only small amounts of aluminum are absorbed into the blood stream, those with normal kidneys will excrete the aluminum in the urine. Unlike calcium, however, aluminum has no useful purpose to the body. In those with kidney problems aluminum may build up in the body causing osteoporosis, muscle weakness, and brain injury. There is some evidence linking aluminum to Alzheimer’s.
    [Show full text]
  • Neonatal Intensive Care Drug Therapy Update: a Bibliography
    LWW/JPNN AS310-13 July 28, 2004 23:11 Char Count= 0 J Perinat Neonat Nurs Vol. 18, No. 3, pp. 292–306 c 2004 Lippincott Williams & Wilkins, Inc. Neonatal Intensive Care Drug Therapy Update: A Bibliography Jason Sauberan, PharmD BIBLIOGRAPHY I. Overview A. Clark RH, Bloom BT, Gerstmann DR Medications Used in Neonatal Intensive Care Units—A Descriptive Study [abstract 3047]. In: Program and abstracts of the 2004 Pediatric Academic Societies’ Annual Meeting, San Francisco, CA. B. Barr J, Brenner-Zada G, Heiman E, Pareth G, Bulkowstein M, Greenberg R, Berkovitch M. Unlicensed and off-label medication use in a neonatal intensive care unit: a prospective study. Am J Perinatol. 2002 Feb;19(2):67–72. C. O’Donnell CP, Stone RJ, Morley CJ. Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics. 2002 Nov;110(5):e52. D. Committee on Drugs. American Academy of Pediatrics. Uses of drugs not described in the package insert (off-label uses). Pediatrics. 2002 Jul;110(1 Pt 1):181–3. II. Anti-infectives A. Linezolid 1. Deville JG, Adler S, Azimi PH, Jantausch BA, Morfin MR, Beltran S, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr Infect Dis J. 2003 Sep;22(9 Suppl):S158–63. 2. Vo M, Cirincione BB, Rubino CM, Jungbluth GL. Pharmacokinetics of Linezolid in Neonates and Young Infants [abstract A-1409]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA.
    [Show full text]
  • 2015 Annual Report
    ANNUAL REPORT 2015 MARCH 2016 TO OUR SHAREHOLDERS ALEX GORSKY Chairman, Board of Directors and Chief Executive Officer This year at Johnson & Johnson, we are proud this aligned with our values. Our Board of WRITTEN OVER to celebrate 130 years of helping people Directors engages in a formal review of 70 YEARS AGO, everywhere live longer, healthier and happier our strategic plans, and provides regular OUR CREDO lives. As I reflect on our heritage and consider guidance to ensure our strategy will continue UNITES & our future, I am optimistic and confident in the creating better outcomes for the patients INSPIRES THE long-term potential for our business. and customers we serve, while also creating EMPLOYEES long-term value for our shareholders. OF JOHNSON We manage our business using a strategic & JOHNSON. framework that begins with Our Credo. Written OUR STRATEGIES ARE BASED ON over 70 years ago, it unites and inspires the OUR BROAD AND DEEP KNOWLEDGE employees of Johnson & Johnson. It reminds OF THE HEALTH CARE LANDSCAPE us that our first responsibility is to the patients, IN WHICH WE OPERATE. customers and health care professionals who For 130 years, our company has been use our products, and it compels us to deliver driving breakthrough innovation in health on our responsibilities to our employees, care – from revolutionizing wound care in communities and shareholders. the 1880s to developing cures, vaccines and treatments for some of today’s most Our strategic framework positions us well pressing diseases in the world. We are acutely to continue our leadership in the markets in aware of the need to evaluate our business which we compete through a set of strategic against the changing health care environment principles: we are broadly based in human and to challenge ourselves based on the health care, our focus is on managing for the results we deliver.
    [Show full text]
  • Atomoxetine: a New Pharmacotherapeutic Approach in the Management of Attention Deficit/Hyperactivity Disorder
    i26 Arch Dis Child: first published as 10.1136/adc.2004.059386 on 21 January 2005. Downloaded from Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder J Barton ............................................................................................................................... Arch Dis Child 2005;90(Suppl I):i26–i29. doi: 10.1136/adc.2004.059386 Atomoxetine is a novel, non-stimulant, highly selective lifespan including a potential requirement for lifelong treatment.4 Because of the limitations of noradrenaline reuptake inhibitor that has been studied for existing treatments and the paradigm shift in use in the treatment of attention deficit/hyperactivity thinking about the management of ADHD, there disorder (ADHD). Data from clinical trials show it to be well is an interest in the development of new pharmacological treatments. tolerated and effective in the treatment of ADHD in children, adolescents, and adults. Improvements were seen ATOMOXETINE HYDROCHLORIDE: A not only in core symptoms of ADHD, but also in broader NOVEL TREATMENT FOR ADHD social and family functioning and self esteem. Once-daily Atomoxetine is the first non-stimulant to be approved for the treatment of ADHD and the first dosing of atomoxetine has been shown to be effective in drug to be licensed for the treatment of ADHD in providing continuous symptom relief. Atomoxetine does adults.5 Atomoxetine was licensed in the US in not appear to have abuse potential and is associated with November 2002 and in the UK in May 2004. At the time of writing, it is under consideration for a benign side effect profile. The development of licensing by the regulatory authorities in a atomoxetine thus represents an important advance in the number of other countries.
    [Show full text]
  • Medications in Pregnancy & Lactation.Xlsx
    Commonly Used Medications in Pregnancy and Lactation Breastfeeding Medications: Indication & Side Notes Comments Acne: Over the counter acne medications are low risk. Acne ● Benzoyl Peroxide products Acne Low risk Clindamycin topical Acne Low risk Erythromycin topical Acne Low risk *Finacea topical Acne Not recommended Proactiv Acne Low risk Salicylic Acid products Acne Low risk Allergies: Actifed (after 13 weeks) Nasal Congestion, Allergies Low risk Afrin Nasal Spray (only for 3 days) Nasal Congestion Low risk Low risk (may ↓ milk Alavert (Loratadine) Allergies supply) Low risk (may ↓ milk Benadryl (Diphenhydramine) Allergies & Nasal Congestion supply) Low risk (may ↓ milk Clarinex Allergies supply) Low risk (may ↓ milk Claritin (Loratadine) Allergies supply) Low risk (may ↓ milk Claritin D (after 13 weeks) Allergies & Nasal Congestion supply) Low risk (may ↓ milk Chlor-Trimeton Allergies supply) Flonase Rhinitis, Seasonal Allergies Low risk Phenylephrine (after 13 weeks) Nasal Congestion use caution Ocean’s Nasal Spray Allergies & Nasal Congestion Low risk Low risk (may ↓ milk Sudafed (Pseudoephedrine) (after 13 weeks) Nasal Congestion supply) Low risk (may ↓ milk Tavist (Clemastine) Allergies supply) ● Please Contact Your Pediatrician concerning use in breast feeding. * Prescription medications Low risk (may ↓ milk Zyrtec Allergies supply) Antibiotics: *Amoxicillin Infection Low risk *Ampicillin Infection Low risk *Augmentin Infection Low risk *Keflex (Cephalexin) Infection Low risk *Cefuroxime Infection Low risk *Duricef (Cefadroxil)
    [Show full text]
  • Application and Review of Pediatric Pharmacotherapy, Sample Chapter
    Application and Review of Pediatric Pharmacotherapy Chapter No. 1 Dated: 29/7/2010 At Time: 16:16:4 Section 1 Neonatal intensive care “Luck is where preparation meets opportunity.” This section consists of 16 medication orders followed by corresponding patient profiles representing pharmacotherapy associated with patients admit- ted to a neonatal intensive care unit. Each patient profile is followed by multiple-choice questions pertaining to the medication order and profile infor- mation. Choose the one best-lettered response to each item. The correct answers are provided at the end of this section. The reader is encouraged to attempt all questions for each case or for the entire section prior to referring to the answers. Moreover, where appropriate, the answer key provides a thor- ough explanation of the correct response and should serve as an additional learning tool for the reader. Application and Review of Pediatric Pharmacotherapy Chapter No. 1 Dated: 29/7/2010 At Time: 16:16:4 2 | Application and Review of Pediatric Pharmacotherapy Medication orders Physician order Patient weight: 2.5 kg Aminophylline 10 mg iv load, then begin 2.5 mg iv q 12 h Obtain theophylline concentration 1 h postinfusion of loading dose Date/time: 12/01/2100 Patient name: Baby Boy Turner Physician: John Craver Patient ID: 111222 Medical profile Patient: Baby Boy Turner Patient weight: 2.5 kg Age: 1d/o Present illness: Apneic episodes Allergies: None Medical history: 33 weeks gestation, Apgar 7 and 9 Labs: pending Medication profile Questions Q1 Which of the following is an acceptable definition of apnea of prematurity? 1 o cessation of breathing for less than 20 s 2 o cessation of breathing for at least 20 s 3 o cessation of breathing for less than 20 s when accompanied by bradycardia A o 1 only B o 3 only C o 1 and 3 only Application and Review of Pediatric Pharmacotherapy Chapter No.
    [Show full text]
  • Mcneil Consumer : Mdl No
    IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA IN RE: MCNEIL CONSUMER : MDL NO. 2190 HEALTHCARE, ET AL., MARKETING : AND SALES PRACTICES LITIGATION : : Applies to: : ALL ACTIONS : MEMORANDUM McLaughlin, J. July 13, 2012 This multidistrict litigation arises out of quality control problems at the defendants’ facility manufacturing over- the-counter healthcare products in Fort Washington, Pennsylvania, which led to a series of recalls of those products. The named plaintiffs assert claims for economic loss on behalf of a putative nationwide class against Johnson & Johnson (“J&J”), McNeil Consumer Healthcare (“McNeil”), and four of their executives. The plaintiffs allege that they overpaid for the defendants’ products as a result of the recalls and the defendants’ scheme to conceal or downplay the scope of the quality control problems. The defendants, who have offered a coupon or cash refund to consumers who purchased recalled drugs, have moved to dismiss the operative complaint, and assert that the named plaintiffs lack constitutional standing and have not met the applicable pleading standard. The Court will grant the defendants’ motion because the plaintiffs have not pled facts that show a cognizable injury in fact, which is required to confer Article III standing. I. Procedural Background This litigation resulted from the consolidation of ten individual actions filed around the country. Haviland v. McNeil Consumer Healthcare, No. 10-2195, was filed in this Court on May 12, 2010, asserting economic injuries arising out of the April 30, 2010 recall of over-the-counter children’s drugs by McNeil, a part of the J&J “Family of Companies.” Eight additional cases, also arising out of the April 2010 recall, were filed in district courts around the country.1 All cases asserted claims for economic injury only, with the exception of Rivera v.
    [Show full text]
  • Caffeine in the Treatment of Pain
    Rev Bras Anestesiol ARTIGOS DE REVISÃO 2012; 62: 3: 387-401 ARTIGOS DE REVISÃO Cafeína para o Tratamento de Dor Cristiane Tavares, TSA 1, Rioko Kimiko Sakata, TSA 2 Resumo: Tavares C, Sakata RK – Cafeína para o Tratamento de Dor. Justificativa e objetivos: A cafeína é uma substância amplamente consumida com efeitos em diversos sistemas e que apresenta farmacoci- nética e farmacodinâmica características, causando interações com diversos medicamentos. O objetivo deste estudo é fazer uma revisão sobre os efeitos da cafeína. Conteúdo: Nesta revisão, são abordados a farmacologia da cafeína, os mecanismos de ação, as indicações, as contraindicações, as doses, as interações e os efeitos adversos. Conclusões: Faltam estudos controlados, randomizados e duplos-cegos para avaliar a eficácia analgésica da cafeína nas diversas síndromes dolorosas. Em pacientes com dor crônica, é necessário ter cautela em relação ao desenvolvimento de tolerância, abstinência e interação medi- camentosa no uso crônico de cafeína. Unitermos: ANALGESIA; DOR; DROGAS, Alcaloide/cafeína. ©2012 Elsevier Editora Ltda. Todos os direitos reservados. INTRODUÇÃO Estrutura química A cafeína foi isolada em 1820, mas a estrutura correta des- A cafeína é um alcaloide presente em mais de 60 espécies ta metilxantina foi estabelecida na última década do século de plantas 4. Sua estrutura molecular pertence a um grupo XIX. Os efeitos não foram claramente reconhecidos até 1981, de xantinas trimetiladas que incluem seus compostos inti- quando o bloqueio de receptores adenosina foi correlacio- mamente relacionados: teobromina (presente no cacau) e nado às propriedades estimulantes da cafeína e de seus teofilina (presente no chá) 1. Quimicamente, esses alcaloides análogos 1. Provavelmente a cafeína é uma das substâncias são semelhantes a purinas, xantinas e ácido úrico, que são psicoativas mais utilizadas no mundo, promovendo efeitos compostos metabolicamente importantes 4.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • STRATTERA Safely and Effectively
    1 HIGHLIGHTS OF PRESCRIBING INFORMATION serious cardiac problems that may place them at increased These highlights do not include all the information needed to use vulnerability to its noradrenergic effects. Consideration should be STRATTERA safely and effectively. See full prescribing given to not using STRATTERA in adults with clinically significant information for STRATTERA. cardiac abnormalities. (5.3) ® • Emergent Cardiovascular Symptoms – Patients should undergo STRATTERA (atomoxetine) capsules, for oral use prompt cardiac evaluation. (5.3) Initial U.S. Approval: 2002 • Effects on Blood Pressure and Heart Rate – Increase in blood WARNING: SUICIDAL IDEATION IN CHILDREN AND pressure and heart rate; orthostasis and syncope may occur. Use ADOLESCENTS with caution in patients with hypertension, tachycardia, or cardiovascular or cerebrovascular disease. (5.4) See full prescribing information for complete boxed warning. • Emergent Psychotic or Manic Symptoms – Consider discontinuing • Increased risk of suicidal ideation in children or adolescents treatment if such new symptoms occur. (5.5) (5.1) • Bipolar Disorder – Screen patients to avoid possible induction of a • No suicides occurred in clinical trials (5.1) mixed/manic episode. (5.6) • Aggressive behavior or hostility should be monitored. (5.7) • Patients started on therapy should be monitored closely (5.1) • Possible allergic reactions, including anaphylactic reactions, angioneurotic edema, urticaria, and rash. (5.8) ------------------------INDICATIONS AND USAGE------------------------------- • Effects on Urine Outflow – Urinary hesitancy and retention may STRATTERA® is a selective norepinephrine reuptake inhibitor occur. (5.9) indicated for the treatment of Attention-Deficit/Hyperactivity Disorder • Priapism – Prompt medical attention is required in the event of (ADHD). (1.1) suspected priapism. (5.10, 17) • Growth – Height and weight should be monitored in pediatric -----------------------DOSAGE AND ADMINISTRATION----------------------- patients.
    [Show full text]
  • SHARED CARE AGREEMENT ATOMOXETINE for ADULT ADHD
    Shared Care Guideline Atomoxetine for Adult ADHD SHARED CARE AGREEMENT ATOMOXETINE for ADULT ADHD Version: Date: Author: Status: Comment: 1 01/2014 Tracey Green Draft Dr Saif Sharif Document Author Written by: Tracey Green Signed: Date: 15/07/2013 Job Title: Pharmacist Mental Health Approval DAC: 07/03/14 Trust Executive Committee date: April 2014 CCG Board date: April 2014 Review Date: March 2016 Effective Date: March 2014 Version Control History: Version: Date: Author: Status: Comment: 1 March 2014 Tracey Green Approved Dr Saif Sharif Shared Care Guideline February 2014 Isle of Wight NHS Trust 01983 524081 Lead Consultant Dr Saif Sharif Lead Nurse Lead Pharmacist Tracey Green Medicines Information 01983 534622 NB: This Shared Care Agreement relates to the Isle of Wight NHS Trust hereafter referred to as the Trust. This shared care guideline has been produced to support the seamless transfer of prescribing and patient monitoring from secondary to primary care and provides an information resource to support clinicians providing care to the patient. It does not replace discussion about sharing care on an individual patient basis. This guideline was prepared using information available at the time of preparation, but users should always refer to the manufacturer’s current edition of the Summary of Product Characteristics (SPC or “data sheet”) for more details. The Trust holds full responsibility for any adverse events preventable by monitoring stated within the agreement at all times that prescribing continues within the limits set by the
    [Show full text]